Category: Oncology

FREGAT Trial (2019): Minimally Invasive Esophagectomy for Esophageal Cancer

Source: NEJM FREGAT Trial Key Points Minimally invasive esophagectomy (MIE) was found to have significantly lower complications and side effects compared to open esophagectomy. The 3 years survival rate was also higher among patients undergoing minimal invasive esophagectomy. Open esophagectomy is known to have significant morbidity ranging from 17.9% to 58%, with up to 6% mortality. Therefore, the..

Read more

PACIFIC Trial (2017): Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

PACIFIC Trial Summary (NEJM 2018): Scott J et al. randomized 713 patients with stage III unresectable nonsmall cell lung cancer (NSCLC) who did not have disease progression after concurrent chemoradiotherapy were randomized to either Durvalumab 10mg/kg body weight twice weekly for 12 months (n=473) or matching placebo (n=236). The primary objective was to assess if..

Read more

AVERT Trial: Apixaban to Prevent VTE in Patients with Cancer

2018, Apixaban to Prevent Venous Thromboembolism in Patients with Cancer, NEJM The AVERT trial evaluated the use of apixaban for preventing venous thromboemboli such as deep venous thrombosis and pulmonary embolism in patients with cancer who were scheduled to start chemotherapy. These patients were at high risk of VTE based on the Khorana score. The point..

Read more